We are live on ! Find out more
NUVL

Nuvalent

Delisted

NUVL was delisted on the 14th of July, 2026.

115 hedge funds and large institutions have $2.57B invested in Nuvalent in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 56 increasing their positions, 30 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more call options, than puts

Call options by funds: $22.5M | Put options by funds: $8.28M

87% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 30

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

10% more capital invested

Capital invested by funds: $2.33B → $2.57B (+$237M)

6% more funds holding

Funds holding: 109115 (+6)

0.7% more ownership

Funds ownership: 107.54%108.24% (+0.7%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

Holders
115
Holders Change
+6
Holders Change %
+5.5%
% of All Funds
1.82%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
15
Increased
56
Reduced
30
Closed
9
Calls
$22.5M
Puts
$8.28M
Net Calls
+$14.2M
Net Calls Change
+$14M

NUVL Hedge Fund Activity: Q3 2023 in Review

115 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Nuvalent (NUVL) for Q3 2023, worth a combined $2.57B — up 10% from $2.33B a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new NUVL positions and 9 closed out — a net gain of 6 holders — while 56 added to existing stakes and 30 trimmed.

The largest buyer was Paradigm Biocapital Advisors, adding an estimated $23M. The largest seller was Avoro Capital Advisors, cutting an estimated $35M.

  • 115 institutional investors held Nuvalent (NUVL) as of Q3 2023, up from 109 in Q2 2023.
  • Funds reported $2.57B of Nuvalent stock for Q3 2023, up 10% quarter-over-quarter.
  • 15 funds opened new Nuvalent positions in Q3 2023 and 9 closed out, a net change of +6 holders.
  • The largest Nuvalent buyer in Q3 2023 was Paradigm Biocapital Advisors, an estimated $23M added.
  • The largest Nuvalent seller in Q3 2023 was Avoro Capital Advisors, an estimated $35M sold.

Based on aggregated 13F filings for Q3 2023.